Adicet Bio Inc (STU:1IJA)
€ 1.189 -0.027 (-2.22%) Market Cap: 100.00 Mil Enterprise Value: -89.85 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 37/100

Adicet Bio Inc at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 11:00AM GMT
Release Date Price: €10.9 (-1.80%)
Michael Chu

Good morning, and thank you for coming to the 2021 Virtual UBS Global Healthcare Conference. My name is Michael, and I'm happy to be your host for this session. Our next presenter will be Chen Schor from Adicet Bio. The Q&A session will follow immediately after the presentation. (Operator Instructions)

I'll now turn it over to Chen. Thank you.

Chen Schor
Adicet Bio, Inc. - CEO, President & Director

Perfect. Good morning, everybody, and thank you for your interest in Adicet. Michael, thank you for inviting us to present at the UBS conference. So at Adicet, we're leading the development of off-the-shelf gamma delta T cells that we engineer to fight cancer. Gamma delta T cells is a therapy that is expected to be an attractive option for patients when we compare it to other allogeneic types of cell therapy such as alpha beta T cells or NK cells or B-specifics. And it's my goal for you guys to understand a little bit the differentiation during this presentation, and I'm happy to address any additional questions in the Q&A.

We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot